310 related articles for article (PubMed ID: 38773983)
1. Actinium-225 targeted alpha particle therapy for prostate cancer.
Bidkar AP; Zerefa L; Yadav S; VanBrocklin HF; Flavell RR
Theranostics; 2024; 14(7):2969-2992. PubMed ID: 38773983
[TBL] [Abstract][Full Text] [Related]
2. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
3. Evaluation of
Bobba KN; Bidkar AP; Meher N; Fong C; Wadhwa A; Dhrona S; Sorlin A; Bidlingmaier S; Shuere B; He J; Wilson DM; Liu B; Seo Y; VanBrocklin HF; Flavell RR
J Nucl Med; 2023 Jul; 64(7):1076-1082. PubMed ID: 37201957
[No Abstract] [Full Text] [Related]
4. Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals.
Ndlovu H; Mokoala KMG; Lawal I; Emmett L; Sathekge MM
PET Clin; 2024 Jul; 19(3):371-388. PubMed ID: 38658230
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer.
Schatz CA; Zitzmann-Kolbe S; Moen I; Klotz M; Nair S; Stargard S; Bjerke RM; Wickstrøm Biseth K; Feng YZ; Indrevoll B; Cruciani V; Karlsson J; Haendler B; Nielsen CH; Alfsen MZ; Hammer S; Hennekes H; Cuthbertson A; Hagemann UB; Larsen Å
Clin Cancer Res; 2024 Jun; 30(11):2531-2544. PubMed ID: 38593212
[TBL] [Abstract][Full Text] [Related]
6. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.
Thiele NA; Brown V; Kelly JM; Amor-Coarasa A; Jermilova U; MacMillan SN; Nikolopoulou A; Ponnala S; Ramogida CF; Robertson AKH; Rodríguez-Rodríguez C; Schaffer P; Williams C; Babich JW; Radchenko V; Wilson JJ
Angew Chem Int Ed Engl; 2017 Nov; 56(46):14712-14717. PubMed ID: 28963750
[TBL] [Abstract][Full Text] [Related]
7. A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes.
Hassan M; Bokhari TH; Lodhi NA; Khosa MK; Usman M
Chem Biol Drug Des; 2023 Nov; 102(5):1276-1292. PubMed ID: 37715360
[TBL] [Abstract][Full Text] [Related]
8. Alpha and Beta Radiation for Theragnostics.
Song H; Sgouros G
PET Clin; 2024 Jul; 19(3):307-323. PubMed ID: 38688775
[TBL] [Abstract][Full Text] [Related]
9. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.
Bicak M; Lückerath K; Kalidindi T; Phelps ME; Strand SE; Morris MJ; Radu CG; Damoiseaux R; Peltola MT; Peekhaus N; Ho A; Veach D; Malmborg Hager AC; Larson SM; Lilja H; McDevitt MR; Klein RJ; Ulmert D
Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15172-15181. PubMed ID: 32532924
[TBL] [Abstract][Full Text] [Related]
10. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
Miederer M; Scheinberg DA; McDevitt MR
Adv Drug Deliv Rev; 2008 Sep; 60(12):1371-82. PubMed ID: 18514364
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR
Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693
[TBL] [Abstract][Full Text] [Related]
12. Actinium-225 in targeted alpha-particle therapeutic applications.
Scheinberg DA; McDevitt MR
Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
[TBL] [Abstract][Full Text] [Related]
13. First Clinical Results for PSMA-Targeted α-Therapy Using
Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
[TBL] [Abstract][Full Text] [Related]
14. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study.
Stuparu AD; Meyer CAL; Evans-Axelsson SL; Lückerath K; Wei LH; Kim W; Poddar S; Mona CE; Dahlbom M; Girgis MD; Radu CG; Czernin J; Slavik R
Theranostics; 2020; 10(6):2612-2620. PubMed ID: 32194823
[No Abstract] [Full Text] [Related]
15. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
[TBL] [Abstract][Full Text] [Related]
16. Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.
Thiele NA; Wilson JJ
Cancer Biother Radiopharm; 2018 Oct; 33(8):336-348. PubMed ID: 29889562
[TBL] [Abstract][Full Text] [Related]
17. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
Kozempel J; Mokhodoeva O; Vlk M
Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
[TBL] [Abstract][Full Text] [Related]
18. Development of
Robertson AKH; Ramogida CF; Schaffer P; Radchenko V
Curr Radiopharm; 2018; 11(3):156-172. PubMed ID: 29658444
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
[TBL] [Abstract][Full Text] [Related]
20. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
Kratochwil C; Bruchertseifer F; Rathke H; Bronzel M; Apostolidis C; Weichert W; Haberkorn U; Giesel FL; Morgenstern A
J Nucl Med; 2017 Oct; 58(10):1624-1631. PubMed ID: 28408529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
